Trial Profile
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMvigor010
- Sponsors Chugai Pharmaceutical; Roche
- 22 May 2023 Status changed from completed to discontinued.
- 14 Feb 2023 Status changed from discontinued to completed.
- 15 Oct 2022 This trial has been completed in Poland(End Date: 14 Jun 2022) according to European Clinical Trials Database record.